Histopathological diagnosis of biopsy samples and margin assessment of surgical specimens are challenging aspects in sarcoma. Using dog patient tissues, we assessed the performance of a recently developed technology for fast ex vivo molecular lipid-based diagnosis of sarcomas. The instrument is based on mass spectrometry (MS) molecular analysis through a laser microprobe operating under ambient conditions using excitation of endogenous water molecules. Classification models based on cancer/normal/necrotic, tumor grade, and subtypes showed a minimum of 97.63% correct classification. Specific markers of normal, cancer, and necrotic regions were identified by tandem MS and validated by MS imaging. Real-time detection capabilities were demonstrated by ex vivo analysis with direct interrogation of classification models.
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Using dog tissue samples, Saudemont et al. evaluate the performance of a mass spectrometry-based analysis of lipids for fast ex vivo diagnosis of sarcomas. This approach may improve the clinical management of sarcomas by facilitating histopathological diagnosis of biopsy samples and surgical margin assessment.
INTRODUCTION
Accurate cancer diagnosis plays a pivotal role in choosing optimal treatment and in consequence is crucial for cancer prognosis. Currently, the presence of the tumor can be detected by means of non-invasive tools such as X-ray scans, positron emission tomography scans, and computed tomography or MRI, which are regularly combined with blood marker assays. However, final diagnosis is established based on the histological examination of a tissue specimen, which is obtained via core biopsy, endoscopic punch biopsy, or surgical biopsy using laparoscopy or laparotomy. In most instances such as sarcoma management, surgical specimens are also subjected to pathological examination to support initial diagnosis and margin status assessment. Histological examination of core needle biopsies remains the gold standard for the diagnosis of sarcomas and related tumors. In these lesions rapid, accurate, or precise diagnosis based on morphology and routine ancillary techniques can be challenging. There is, thus, an ample need for a molecular technique that could ameliorate and expedite diagnostic decisions.
Soft tissue tumors form a class of highly heterogeneous mesenchymal lesions, arising from tissues such as fat, muscle, cartilage, fibrous connective tissue, and the pericytes of small blood vessels in the subcutis and from skin. They cover an extensive range of morphological differentiation patterns. Current diagnostic methods include basic analytical processes such as standard histological staining, as well as more elaborate techniques such as immunostaining and molecular genetics, which include fluorescent in situ hybridization for the detection of gene amplification and rearrangements and RT-PCR for the detection of characteristic or specific gene fusions (Antonescu, 2006; Jaber and Kirby, 2015) . Although these tests are limited by the fact that they cannot be multiplexed, they are adapted to and widely used in routine clinical practice especially for sarcomas presenting a specific line of differentiation. But this differentiation may be lacking in a substantial number of cases, rendering classification difficult. In addition, a morphologically bland-looking tumor may not necessarily follow a clinically benign course such as low-grade fibro-myxoid sarcoma or low-grade myxofibrosarcoma, both of which are classified as malignant tumors (Fletcher et al., 2013) . Further, some rare tumors previously considered to be potentially malignant have been re-classified as benign. For example, the previously reported well-differentiated spindle cell liposarcoma (Mentzel et al., 2010) no longer belongs to the spectrum of atypical lipomatous tumor, but has a close relationship with spindle cell lipoma, now being termed fibrosarcoma-like lipomatous neoplasm (Deyrup et al., 2013) . This illustrates the uncomfortable situation where, because of equivocal phenotypic overlap and imprecise prognostic correlation, the morphological distinction between benignity and malignancy in tumors not showing characteristic genetic alterations is not easy. This ambiguous setting is commonly encountered in benign myofibroblastic lesions versus low-grade spindle cell sarcoma, cellular schwannoma, or atypical neurofibroma versus low-grade malignant peripheral nerve sheath tumor, and cellular or atypical fibrous histiocytoma versus true sarcoma. The case of pleomorphic lipoma versus pleomorphic liposarcoma may represent an especially challenging diagnostic pitfall: they are morphologically almost identical but the former is benign, whereas the latter is highly malignant (Azzopardi et al., 1983) .
These considerations underline the necessity to develop validated molecular techniques for rapid and accurate classification to improve diagnostic accuracy of tumor subtypes in human sarcomas. Emerging techniques with promising applications such as mass spectrometry (MS) may be of great value as an adjunct to existing tests. Microbiopsy-based diagnosis is currently considered to be the standard protocol prior to treatment, so that diagnostic precision is crucial for clinical management. Another challenge for sarcoma management is molecular assessment of surgical margin status, which plays a key role in prognosis. The best patient care possible is to establish a correct and precise initial diagnosis followed by the excision of the tumor with documented clear margins to avoid surgical and oncological complications, such as local or distant relapse and wound healing complications (Aerts et al., 2014; Liu et al., 2011; Pena et al., 2014) .
MS has long been in the focus of interest for the direct analysis for discriminating cells of different phenotypes using tissue sections of patient biopsies (Le Rhun et al., 2015 Vaysse et al., 2017) . But in the context of intraoperative tissue analysis, the main challenge remains to develop an MS instrument compatible with in vivo analysis working in a surgical environment. The Intelligent Knife (iKnife) system (Balog et al., 2013; Schafer et al., 2009 ) allows monitoring during surgery by the real-time mass spectrometric analysis of the aerosol liberated during electrosurgical tissue dissection. The in vivo and ex vivo application of the iKnife technique has successfully been demonstrated for breast and ovarian cancers (Phelps et al., 2018; St John et al., 2017) . More recently another system, called MasSpec Pen, was described (Zhang et al., 2017) , where sampling of tissues is achieved by aqueous extraction and the aqueous extract is analyzed by MS. However, this device must be placed in tight contact with the tissue for analysis, hence limiting its use for cancer research due to possible contamination of the device with tissue debris. So far, the MasSpec Pen was only demonstrated ex vivo for laboratory model samples.
Veterinary canine patients-similarly to humans-develop spontaneous tumors that share many features similar to the human disease (Takashima-Uebelhoer et al., 2012) . Moreover, oncological surgery is a frontline treatment for both human (Abramson, 2010; Carpenter et al., 1991; Diamond et al., 1999; Greenfield et al., 1995; Lewis, 1995; Misdorp and Hart, 1976; Pluhar et al., 2000; Schneider, 1970; Schwyn et al., 1998) and veterinary patients (Caceres et al., 2016; Liu et al., 2011; Pena et al., 2014) . Specifically, soft tissue sarcomas and osteosarcoma in dogs have similar morphological appearances, clinicopathological presentation, and phenotypes as in humans and have been shown to be an excellent comparative model. In current practice, canine sarcomas are diagnosed using human guidelines hence the diagnostic procedures face similar challenges. MS imaging (MSI) has already been demonstrated to provide excellent prognostic information on this group of diseases (Lou et al., 2017) .
In the present work, we evaluate the potential of a recently developed MS technology called SpiderMass (Fatou et al., 2016 (Fatou et al., , 2018a (Fatou et al., , 2018b Salzet et al., 2017) in addressing the needs for sarcoma management.
RESULTS

SpiderMass Instrument
The SpiderMass technology has been designed for minimal invasiveness, allowing information to be obtained without causing in-depth tissue damage. The technology is based on a unique micro-sampling probe, built in-house, that uses laser desorption. The system performs MALDI-MS under ambient conditions, several meters away from the mass analyzer. This is achieved by resonantly exciting the endogenous water of biological tissues. Because water is in large excess within biological tissues (>50%) solvating practically all molecular species present, it can act as a MALDI matrix. Resonant excitation is obtained by tuning an optical parametric oscillator (OPO) laser system to the most intense absorption band of water at l = 2.94 mm (Berkenkamp et al., 1996; Laiko et al., 2002) . The high absorption coefficient (a z 3 3 10 À4 cm À1 ) of the water O-H stretching band and the relatively low laser energy used (3-5 mJ/pulse) ensure that only a very low amount of material is ablated (penetration depth: few mm/laser shot). Since the system is based on the MALDI principle, ion yields are sufficient to provide good sensitivity without post-ionization. As expected, only intact molecular ion signals are observed with the water matrix, preventing the analyte molecules from receiving an excessive amount of internal energy and undergo unwanted fragmentation. Figure 1A shows a schematic representation of the SpiderMass instrument illustrating the modifications of the setup described previously (Fatou et al., 2016) . This version of the prototype includes an infrared (IR) OPO pumped by a nanosecond Nd:YAG laser and connected to a Q-TOF instrument. The entire system is equipped with wheels allowing for easy transportation and deployment. At the exit of the OPO source the laser beam is injected inside the fiber ( Figures 1B and 1C) . The distal end of the fiber is directly connected to a handpiece equipped with a focusing lens to create a laser spot size of 500 mm in diameter at the focal point ( Figures 1C and 1D ). In this prototype, the optical fiber advantageously replaces the set of reflecting mirrors used to direct the incident laser beam to the sample surface and avoids incorporating the entire laser system into the handpiece. The optical fiber and handpiece now permit maneuverability over the sample and makes it suitable for analyzing surfaces of variable geometries especially when using a long optical fiber (>1 m). The ion transfer tubing is likewise attached to the handpiece ( Figures 1D and 1E ) to collect the ablated material ( Figure 1E ). The proximal end of the transfer tubing is connected to the ion source inlet of the mass spectrometer. This prototype operates both for ex vivo and in vivo analysis of surfaces by scanning the tissues, enabling real-time molecular signature acquisition under minimally invasive conditions. Figure 1E shows the laser beam leaving only a white trace on the tissue during real-time analysis of the user's skin which can be simply wiped off. In the current work, the instrument was used for building an ex vivo classification model by screening biopsies collected from canine subjects in a veterinary oncology practice. Figure 1F shows the workflow used to acquire spectra for classification. The obtained biopsies were divided into two parts. The first half was saved and stored at À80 C for further analyses. The second half was sectioned into: (1) a 1-mm-thick slice for SpiderMass analysis, and (2) several 10-mm sections for MALDI-MSI and hemalun-phloxine-saffron staining (HPS). The optical images of the stained sections served as morphological controls and were used to define the normal, cancer, and necrotic zones.
Classification Models for Sarcoma Tumors
Sarcoma is a uniquely complex cancer type because it has more than 50 histological subtypes and is thus probably the most diverse and heterogeneous of all cancers (Bleloch et al., 2017; Skubitz et al., 2008; Stiller et al., 2013) . We developed a classification model for a collection of canine sarcomas using lipidomic molecular signatures collected by the MS analysis of histologically annotated biopsy specimens (Table S1 ). In brief, the median age of the animals was 9 years, and 32 were pure breeds of various types, while one was a crossbreed. The majority of the biopsies fell into the three main categories including: fibrosarcoma (6 biopsies), osteosarcoma (5 biopsies), and undifferentiated sarcoma (6 biopsies); the osteosarcomas were further subtyped as osteoblastic (4 biopsies) or osteoblastic and chondroblastic (1 biopsy) sarcomas. Of the biopsies that have been graded (17 biopsies), 4 were grade I, 7 were grade II, and 6 were grade III; the latter is comprised mostly of undifferentiated pleomorphic sarcoma.
Following the acquisition of the MS spectra in both positive and negative ion modes, we were first interested in the possible differentiation between cancer and normal tissues. Results of the multivariate analysis using principal-component analysis (PCA) from the generated spectra acquired from the 33 biopsies are summarized in Figure 2A for the positive ionization mode and Figure 2B for the negative ionization mode. The first three principal components (PCs) explain 30.4% of the variance for the positive mode acquisition and 31.4% for the negative mode acquisition. Good separation is observed among the scores for the normal and cancer groups as shown in in the data plane defined by the first two PCs. The features extracted using PCA were subjected to supervised analysis using linear discriminant analysis (LDA) (Balog et al., 2013; Schaefer et al., 2009) , with the spectra grouped into two classes for cancer and normal tissues. It can be observed from LDA that better discrimination was obtained for data taken in positive ion mode ( Figure 2C ) than in negative ion mode ( Figure 2D ). Excellent cross-validation results were obtained using the ''leave one patient out'' method with 99.94% and 95.37% correct classification rates with and without outliers in the positive mode and 97.63% and 94.54% in the negative mode (Table 1) . PCA results reflect the heterogeneity of the cancer group, which is more spread than the normal tissues. We suspect that the subset of spectra can be attributed to the necrotic zones which are indicative of higher-grade sarcoma.
We tested this hypothesis on a fibrosarcoma biopsy (sample Ds2) sample of grade III, which contains normal, cancer, and necrotic zones as confirmed by HPS staining ( Figure 3A ). Using SpiderMass, a 1.7-min acquisition was done on the Ds2 sample, performing discrete micro-sampling using 10-s then 5-s laser irradiation periods per point with one spectrum generated per second to analyze the three different regions of the tissue. The total ion count for the 5-s irradiations (7-14) with the individual acquisitions colored according to the corresponding region is shown in Figure 3A , bottom, and sample spectra (averaged from the 5-s irradiations) recorded per region are shown in Figure 3B . The MS spectra of each of the analyzed regions clearly demonstrates that necrosis itself possesses a specific molecular signature when compared with viable cancer tissues.
Considering these results, the PC-LDA classification model shown in Figure 2 was reconstructed taking necrosis into account as a distinct group in the classification system. The LDA result of the classification model from positive ion mode data shows the separation of the necrotic zone group (blue) from the normal (green) and cancer (red) groups, when using individual spectra to generate the model ( Figure 3C ). From PCA, we can observe that necrosis explains a part of the heterogeneity of the cancer group but not all, which is not surprising considering the numerous subtypes that exist in sarcoma ( Figure S1 ). Leave one patient out cross-validation based on the normal/cancer/necrosis classification shows 99.06% and 81.89% correct classification rates (Table 1) .
Modeling of a Real-Time Tissue Analysis and Classification
To demonstrate the utility of our model in a surgical setting by classifying tissues in real time we simulated an in vivo application by analyzing ex vivo a fibrosarcoma biopsy (labeled Ds2) containing different histological regions. The model generated by PC-LDA for normal/cancer/necrosis classification was loaded into the OMB-Recognition software and tested on this sample. An animation, including a video of the real-time classification, is shown in Video S1. This depicts the acquisition of individual spectra as the laser probe samples over the entire tissue along its longitudinal axis, as well as the automated comparison with the model as a function of the input spectrum. The readout is a prediction of the cancer, normal, and necrotic classes, which is displayed with less than a 1-s time delay compared with spectral acquisition. Readout is given by a color code according to the class in the classification model ( Figure 3C ), i.e., green for normal tissues, red for cancer, and blue for necrosis. As the laser beam progressively passes over the tissue, it will come across normal, then cancer, and finally necrotic areas. The real-time classification readout did not show any failure in classification, with class similarity values always above 91%. Table S1 .
Classification Models for Sarcoma Grading
Interestingly the normal versus tumor versus necrosis classification (Figures 4A and 4B) gives an easy access to the discrimination of grade III tumors. Since necrosis is more predominant at grade III and is one of the criteria taken into account in grading, this shows good correlation with histological standards (Trojani et al., 1984) . Examination of the PCA features verify the presence of different PC loadings contributing to the variance observed for each group, notably for the first component, which explains 42.8% of the variance (16.9% and 13.7% for the PC2 and PC3 scores, respectively, for a total of 73.4% of variance explained by the first three components).
To assess the classification strength of our method, we explored the possibility of generating a classification model based on tumor grade. Figures 4C and 4D show the model after re-classifying the averaged spectra based on tumor grade assigned by the pathologist. The PCA plot ( Figure 4C ) shows good separation of the normal and grade III classes from each other and from grades I and II. In contrast, grades I and II are only partially separated from each other. Osteosarcomas are not graded but assigned to a separate class by the veterinary pathologist, named N/A (not assigned). The spectra recorded for these samples group with the grade I and II samples in the PCA representation. The LDA score plot ( Figure 4D ) shows good intergroup separation, suggesting distinct molecular signatures for each grade. In this plot, interestingly, the N/A group clusters closer to the grade II class, highlighting that these groups share similar molecular signatures. For three of the biopsies, namely Ds6, Ds18, and Ds22, the PCA plot shows that they cluster with the grade III class, rather than grade II or N/A as attributed by the pathologist. Ds18 is an osteosarcoma (usually graded N/A); but the presence of massive osteolysis could explain its similarity to necrosis and grade III. Similarly, Ds22 is an undifferentiated sarcoma that was not graded by the pathologist but was noted to bear major necro-hemorrhagic changes. Finally, for Ds6, the diagnosis was difficult but suggested a grade II fibrosarcoma, and it shows a molecular profile closer to grade III. Thus, the models based on SpiderMass molecular signatures could serve as an aid for the pathologist in such ambiguous cases. Cross-validation using a four-class model considering normal, grade I, grade II, and grade III (Table 1) shows correct classification rate of 83.76% and 70.50% excluding and including outliers, respectively.
To determine which lipids are discriminative of the normal, cancer, and necrotic classes, we extracted the top five loadings that significantly contributed to the variance observed in the scores of the first PC of the three-class PC-LDA model (Figure S2A) . A few examples of these discriminative markers are presented together with the boxplots of the normalized intensities recorded for the different tissues ( Figure 5 ). Figure S2B shows the complete boxplots for the top five loadings of each group, and Data S1 shows the statistical results used to generate the boxplots. 
Biomarker Identification and Cross-Validation by MALDI-MSI
The biomarkers we found to be discriminant in the normal/cancer/necrosis areas with SpiderMass were identified by tandem MS (MS/MS) and validated by conventional UV-MALDI-MSI approach. Structural elucidation was performed by on-tissue MS/MS analysis using SpiderMass connected to a high-resolution Orbitrap mass spectrometer. The identification was performed by interrogation of the LIPID MAPS database using accurate m/z measurement of parent followed by a manual assignments of MS/MS fragment ions to confirm identification. Figure S3 shows an example MS/MS assignment obtained for m/z 739.55, which was specific to the cancer area. A zoom of the MS/MS spectrum shows that the precursor ion mass at m/z 739.4667 was the most intense peak isolated in this experiment. The MS/MS spectrum shows potassiated cyclophosphate ion (m/z 162.9556) as the most dominant fragment, as well as peaks arising from the neutral loss of cyclophosphate (m/z 615.4745) and its potassiated adduct (m/z 577.5186), which confirm the potential assignment as PA(36:2) obtained by library search. m/z 485.3025 corresponds to the neutral loss of the C16:1 fatty acid, thus confirms this lipid as the potassiated phosphatidic acid PA (20:1/16:1). Other MS/MS assignments can be found in Data S2 and they are also summarized in Table S2 . Lipids contributing to the discrimination between normal/cancer/necrosis tissue regions belong to different lipid classes, mainly triacylglycerols (TGs), phosphatidylglycerols (PGs), phosphoethanolamine (PE), and sphingomyelins (SMs). Many TGs are specific to the normal regions, whereas glycerophospholipids such as PG, PE, and PA are found more often in the cancer area and SM in the necrotic part of the tissues. Of note, the assignments enable determination of fatty-acid chain length and unsaturation number; however, the position of the double bonds in the fatty acyl moieties could not be identified. The presence of PA in the cancer region is in line with data showing that PA is involved in regulating the mammalian target of rapamycin (mTOR)-mediated signaling, which promotes cancer cell survival (Dancey, 2010; Foster, 2009) , and that SMs are implicated in cancer metabolism and apoptosis pathways (Ogretmen, 2018) . Nine biopsies representing the different types of sarcoma analyzed with SpiderMass were also examined using conventional vacuum UV-MALDI-MSI for validation purposes on 10-mm tissue sections of the respective specimens. MALDI-MSI is a molecular imaging technique (also called molecular histology) and is now recognized as the gold standard for molecular imaging. It has been shown to enable the localization of several biomarkers, including marker lipids in oncology applications (Arafah et al., 2014; Carter et al., 2011; Walch et al., 2008) . After MALDI imaging, data collected from the nine biopsies were subjected to spatial segmentation to identify the different molecular areas of the tissues ( Figure S4 ). This led to principal discrimination of three areas which were attributed to normal, cancer, and necrosis areas as assigned from the HPS staining of adjacent sections ( Figure S4A) . PCA of the regions of interest defined from these clusters grouped according to normal, cancer, and necrosis groups are shown in Figure S4B . Very interestingly, a subclassification between the different subtypes of sarcoma was shown by plotting the scores of the first PCs. Discriminatory m/z values observed in these datasets were compared with the discriminatory m/z obtained using SpiderMass data. The cancer-specific peaks identified from the MALDI-MS images, namely m/z 713.46 and m/z 739.47, were also identified as cancer markers in the model generated from the SpiderMass dataset (Table S2) . Examples of ion images of peaks identified by the SpiderMass and the MALDI-MSI data are depicted in Figure 5 ; the complete set can be found in Figures S5 and S6 . This gives a cross-validation of the data obtained by the classification model built from SpiderMass data. (A) Examination of the HPS-stained section of Ds2 fibrosarcoma shows three distinct regions identified as necrotic, cancer, and normal by the pathologist. The mirror tissue to this annotated section was analyzed with SpiderMass. Spots indicate where analyses were conducted (1-14), while the arrows indicate direction of acquisition starting at 1. Graph below the HPS image shows the total ion count for 5-s acquisitions (7-14). (B) Sample averaged MS spectra corresponding to one zone of each of the normal, cancer, and necrosis regions. (C) LDA representation of the PC-LDA model using a three-class scheme (normal, cancer, and necrosis). This model was built from the individual spectra recorded in the MS-positive ion mode. See also Figure S1 and Video S1.
Subtyping of Sarcoma Tissues Using SpiderMass
To further assess the classification performance of SpiderMass, we looked at establishing a classification model using the different sarcoma subtypes plus normal tissues from the patient cohort (Table S1 ). LDA representation resulting from the classification models using the MS spectra recorded in positive mode and negative mode according to sarcoma subtypes from the four most represented classes (osteosarcoma, fibrosarcoma, undifferentiated, and normal) are shown Figure 6 . Normal tissue is represented by common connective fibro-vascular and adipose tissue. Very good separation of these groups is observed in both positive ( Figure 6A ) and negative ( Figure 6B ) ion modes, although slightly better group separation is again observed for the positive ion mode. Since fibrosarcoma is a tumor derived from connective tissues, the differentiation between classes is to be attributed to the carcinogenesis process rather than the tissue origin. In some cases, the classification for sarcoma subtypes was not possible, due to the low number of samples in certain classes. Even though this was the case, specific molecular signatures were observed for different subtypes of sarcoma, as demonstrated by the distinct spectral profiles from m/z 600-1,000. This is demonstrated by example spectra acquired for each subtype in the positive mode ( Figure S7A ) and in the negative mode ( Figure S7B) . Although certain signals are shared between different groups, neither their intensity nor their global molecular signature is conserved in all 11 classes. Thus, the models show that sarcoma subtyping at the level of osteosarcoma, fibrosarcoma, undifferentiated, and normal tissues is possible using spectra acquired by the SpiderMass technology. This is highly interesting since pathologists struggle to achieve this classification using conventional techniques. For the other subtypes of sarcoma, which are less common, we obtained encouraging results shown in Figure S8A for positive and in Figure S8B for negative ion mode. We are planning to validate these results in the future using a statistically well-powered number of subjects. Figures 7A and 7B show the implementation of SpiderMass prototype into an operating theater. The instrument was operated on dog patients in vivo to confirm the low invasiveness of the technology in the context of surgery. It was also assessed for extemporaneous analysis on the bench during the course of surgery. Video S2 shows the use of the SpiderMass system during an actual surgical operation. In the video, a skin biopsy and a sample body fluid were analyzed extemporaneously using the SpiderMass system. The video also demonstrates the in vivo application of the system, using a 1.5-m laser fiber that allows the probe to be handled remotely from the instrument.
Implementation of SpiderMass in the Operating Room
DISCUSSION
Our study shows that SpiderMass technology enables the acquisition of histologically specific molecular signatures (or molecular barcoding) in different sarcoma-type tumors. On one hand, developments in molecular signatures aimed at being more and more specific to cell phenotypes. On the other hand, there is great need to easily distinguish cancerous tissue from benign ones as there is no single universal discriminant biomarker currently available for all such cases. Moreover, tumor types as well as tumor grades can be established. Indeed, using the MS molecular profiles, classification models are created and successfully cross-validated. Models based on cancer/normal, cancer/normal/necrotic, and tumor grade or cancer subtype classification schemes all showed better than 97% correct classification rates for negative mode and 99% for positive mode, excluding outliers. The specific markers of the normal, cancer, and necrotic regions found with SpiderMass were identified by MS/MS and then validated by MALDI-MSI. Finally, we demonstrated that the instrument allows for in situ, real-time diagnosis using the established classification models.
A close relationship exists between clinical outcome and the efficiency of cancer cytoreduction or complete tumor resection. Despite the large panel of different technologies, it is still extremely difficult for surgeons to assess if they completely removed the tumor tissues. Due to this, in our Comprehensive Cancer Center, conventional intraoperative frozen section is not readily used for surgical margin evaluation in sarcomas, as this is far more reliably performed on the formalin-fixed paraffin-embedded surgical specimen. In the case of unexpected microscopically positive margins after primary resection, a second surgery can be planned to remove residual tumor tissue and ensure adequate local control. It is clear there is an unmet need for an instrument that allows the surgeon to characterize tumor margin status with optimal accuracy at the molecular level and in real time during the surgery avoiding all the risks associated with other resections. The desired features for this technology would include rapid analysis, high sensitivity and specificity, and low invasiveness. The recently introduced iKnife technology meets most of these criteria; however, as a combination of dissection tools with MS, it is highly invasive. Similarly, SpiderMass is capable of remote (several meters away) and in situ analysis, as the optical fiber allows for flexibility of the sampling probe. The handpiece format and extended transfer tube also provides maneuverability to permit sampling of uneven surfaces during intraoperative conditions. All these parts can be sterilized and do not have to be in contact with the surface to sample during analysis, thus minimizing possible contamination. In contrast to the iKnife, the technology is minimally invasive, allowing for the analysis of tissue surfaces before making any surgical decisions. In addition, because the laser energy per pulse is low and because the beam is mostly absorbed by ambient water, no special care needs to be taken when working with the IR laser. Similar wavelength lasers (Er:YAG lasers) are routinely used for eye surgery and cosmetic interventions. For these reasons, Figure S6B . Normalized against the total ion count, intensities are log10 transformed and represented with boxplots using the Tukey method for whiskers definition. The box extends from the 25th to 75th percentiles. The line in the middle of the box is plotted at the median. The up and down whiskers are represented at 1.5 times the distance between those 25th and 75th percentiles, and all points beyond the whiskers are represented as individual point dots and depict the outliers. m/z 687.65 was found to be significantly different for both cancer and necrosis zones compared against the normal zone. *p % 0.05, ***p % 0.001, yp % 0.0001. For the MALDI images, color bars indicate maximum intensities after normalization against TIC. Ds1, myosarcoma; Ds2, fibrosarcoma, containing normal and necrotic zones; Ds3, hemangiopericytoma; Ds4, MPNST; Ds18, osteosarcoma; Ds19, splenic sarcoma; Ds20, histiocytic sarcoma; Ds24, GIST; and Ds26, normal tissue. *p % 0.05, ***p % 0.001, yp % 0.0001. See also Figures S2-S6 , Table S2 and Data S1 and S2.
surgeons could use the instrument to define excision margins with great accuracy before making their decision on the further removal of surrounding tumor tissue.
The animation shown in Video S1 demonstrates how the SpiderMass instrument could be used in the operating room while surgical procedures are being performed. Once the handpiece is positioned over the area of interest, the laser is activated and spectral acquisition is performed. The acquired spectra are then interrogated using the pre-constructed classification model and a readout identifying the analyzed region provides tissue classification in real time (<1 s time delay), similarly to the previously described algorithms (Balog et al., 2013) . The feedback to the user is a traffic light system related to the class and the probability of correct classification. The handpiece is then moved progressively on the tissue until the entire area of interest has been analyzed with a continuous readout provided to the user. In the case of the presented example, a fibrosarcoma biopsy containing all three tissue types was analyzed. Screening of the biopsy was achieved within a few minutes (1.5 min) and the process was only limited by the speed of manual scanning, demonstrating the rapid information delivered by the SpiderMass instrument. The SpiderMass system can analyze directly the raw biopsy tissues and does not require any sample processing since it has been designed to operate under in vivo conditions and provides results within a few minutes of acquisition.
Finally, Video S1 illustrates the potential of SpiderMass for tumor margin definition. Even if the surgeon identifies the cancer/ normal tissues, it is extremely difficult to define its excision margins with sufficient accuracy. This remains an important challenge in surgery because of the tight relation between clean excision margins and local recurrence and patient survival. If a proper classification model is defined with tumor/normal tissues, the real-time classification will allow to accurately define the tumor margins while avoiding removal of healthy tissues. We envision that future development of this technology will allow for automatic laser switch on the handpiece, allowing for easy tuning. In addition, we would like to add a camera for acquisition of images alongside the classification results.
The classification model was initially constructed for the instrument to distinguish cancer zones from benign or normal ones as this is the most important piece of information that surgeons need to make decisions. Such decisions are crucial as they can influence surgery time and removal of unaffected tissue, and consequently might affect patient comfort and surgical outcome. In Figure 6 . LDA Representation of the Classification Models for Sarcoma Subtyping Models were established using the averaged MS spectra recorded both in positive (A) and negative (B) ion mode from the main classes of the cohort (osteosarcoma, fibrosarcoma, undifferentiated, and normal). See also Figures S7 and S8. addition, real-time diagnoses of tumor grade and cancer subtype are equally important. These parameters rely on the creation of strong models that should be built based on classifiers common to most or all sarcoma subtypes. They should also be independent of individual variability and/or the presence of histologic features shared with other pathologies, such as inflammation, immune cell infiltration, etc. In this regard, the cohort included 11 subtypes and 5 grades (3 tumor grades, normal, and N/A) of a cancer type. The database is expected to continuously develop as we constantly recruit more patients and gather more biopsies. The initial model was expanded considering necrotic zones, followed by grading and then subtyping to further improve the precision of the classification without sacrificing its good classification rate. As previously mentioned (Balog et al., 2013) , increasing the number of classes in the supervised multivariate model compromises its identification efficiency. However, this problem can be mitigated by introducing multilevel, hierarchical classification models (Galea et al., 2017) . Having such a classification system is extremely useful in clinical practice because it reduces the labor-and expertiseintensive procedures involved in grading and subtyping tumors. We thus explored this possibility by regrouping the acquired spectra based on their grades and subtypes according to histopathological data. Our preliminary results show the possibility to construct such models for even more classes (here 5 for grading and 11 for subtyping) using SpiderMass technology.
In this work, we built a canine sarcoma classification model based on lipid profiles. Lipids are a class of abundant biomolecules that are readily detected by MS and their use in the generation of tumor classification models has been demonstrated notably by MSI (Eberlin et al., 2012) . Multiple studies have identified key lipids implicated in various pathobiochemical processes, including metabolic remodeling and altered signal transduction pathways. For instance, in myxoid liposarcomas, Willems et al. . m/z 881.75 and m/z 907.77 were also detected in our study, but were instead associated with normal tissue since they contribute largely to the variance observed between the three groups, in accordance with previous findings where TGs decrease in high-grade sarcomas (Willems et al., 2010) . Thus, the implication of these lipids in the shaping of our classification model corroborates with their potential role in cancer, as reported by other groups. This validates the efficiency of the multivariate approach used to generate the model based on the SpiderMass data.
In summary, we demonstrated that SpiderMass can generate a strong sarcoma classification model based on lipid MS molecular profiles acquired directly from canine tumor biopsies. We have presented the two potential advances supported by the technique, precise and rapid diagnostic classification of soft tissue tumors suspected of sarcoma on biopsy and accurate molecular intraoperative surgical assessment. Any clinical implementation of the technique in human sarcoma management requires beforehand validation on a great number of patients. A multi-center participation in a large-scale prospective trial seems to be the appropriate approach considering that sarcomas are a relatively rare entity. But this must be first supported by preliminary proof-of-concept validation studies on a small number of samples, such as the one presented here, whose results seem to be promising, and which are soon to include human tumors. Standardization of the method and validation of SpiderMass with existing techniques will be an important issue to resolve prior to its clinical use. Well-constituted databases also are paramount. We think that MS should ideally be integrated in pathology laboratories (in specialized centers at least) to achieve a uniform diagnostic workflow with existing methods and this would most probably prove to be a powerful incentive to pathologists and clinicians alike to focus on the extended range of diagnostic possibilities as well as on insights in disease mechanisms offered by the technique in cancer management.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Pathology Review and Histology Control
For histology, one veterinary pathologist (QP) read and annotated HPS stained tissues, and one human sarcoma board certified pathologist (Y-MR, Oscart Lambret Center) commented and validated these annotations. The pathologists were blind to any information about the acquisition from MS studies. The annotations were done on Hemalun/Phloxine/Saffron (HPS) stained tissues. For HPS staining, a 10-mm thick tissue slice consecutive to the SpiderMass-analyzed tissue was treated with hemalun solution for 1 min and rinsed with tap water. Then the tissue section was stained in phloxine 0.1% solution for 10 s and rinsed with tap water before dehydration in 70% and 100% ethanol baths. Finally, the sections were dipped in saffron for 5 s, rinsed twice in alcohol, cleaned in xylene, and mounted with cover slips and the EUKITT Ò slide mounting medium. After HPS staining, the nuclei were colored dark blue, the cytoplasm pink, and the conjunctive tissue orange. The stained slide was scanned for digital image acquisition using the Pannoramic MIDI slide scanner (3DHISTECH LTD. Budapest, Hungary) and the images were viewed and exported using Pannoramic viewer 1.15.
METHOD DETAILS Experimental Design
The data were collected and processed in blind after keeping the anonymity of patients using an internal laboratory labeling. All samples of the cohort were analyzed and since sarcoma is a very heterogeneous class of cancer originating from various types of tissues, we took great care that features discriminating the different types of tissues contributed less weight to the classification model than the other features of interest such as grading or typing.
No patients or generated data were excluded from the study and outliers were defined per se when their value was more than 5 times the SD of the mean. All cross-validation results are shown with and without the outliers taken into account. The tissues were analyzed in 5 different locations to replicate the measurement and in both modes of analysis.
Tissue Preparation
After removal, the fresh biopsies were immediately snap-frozen in liquid nitrogen and stored at À80 C until use to avoid tissue degradation. When possible, distant healthy tissues and tumor margins were sampled as well. The tissues were warmed up to À20 C in a cryostat (Leica Microsystems, Nanterre, France) before preparation according to the workflow presented in Figure 1F . Using a metallic tissue cutting matrix (Ted Pella. Redding, California, USA) as a guide to obtain a neat surface, the tissues were cut in two halves and one was kept frozen in case further experiments would be needed. On the other half, a 1-mm thick slice was cut to be used for the SpiderMass analysis. Considering that we use resonant excitation of water molecules this thickness is needed to slow down the drying of the tissue during sampling. The remaining tissue was cut at 10 mm with the cryotome. Two sections were deposited onto polylysine-coated slides by finger-thawing. One was used for Mass Spectrometry Imaging (MSI) analysis while the other was stained with HPS and served as morphological control. This workflow was designed to ensure that the tissue used for MSI reflects the true composition of the tissue surface analyzed by SpiderMass and of the morphological control.
SpiderMass Analysis
The global design of the instrument setup is described in a previous study (Fatou et al., 2016) . Briefly, the system is composed of three parts including a laser system for micro-sampling of tissues set remotely, a transfer line allowing for transfer of the micro-sampled material to the third part, which is the mass spectrometer itself. The first part is composed of a tunable wavelength OPO which is tunable between 2.8 mm to 3.1 mm (Radiant version 1.0.1, OPOTEK Inc., Carlsbad, USA) pumped by a pulsed Nd:YAG laser (pulse duration: 5 ns, l=1064 nm, Quantel, Les Ulis, France). A biocompatible laser fiber (450 mm core diameter; length of 1 m, Infrared Fiber Systems, Silver Spring, USA) is connected to the laser system output and a handpiece including a 4 cm focusing lens is attached to the end of the laser fiber. The handpiece with a 4 cm focusing lens allows the user to hold the system and screen the surface of raw tissues at a resolution of 500 mm. In these experiments the irradiation time was fixed to 10 s at 4 mJ/pulse laser energy corresponding to a laser fluence of 2.03 J/cm 2 . The laser energy was measured at the focal point of the focusing lens using a power meter (ThorLabs, Maisons-Laffitte, France). The second part of the system corresponds to a 3 m length transfer line made from a Tygon ND 100-65 tubing (2.4 mm inner diameter, 4 mm outer diameter, Akron, USA). The transfer line is attached on one side to the laser handpiece at the end of the laser fiber and on its other side directly connected to the mass spectrometer (Synapt G2-S, Waters, Wilmslow, United Kingdom) from which the conventional electrospray source was removed and replaced by an atmospheric pressure interface described elsewhere (Balog et al., 2015) . The SpiderMass prototype system used for these experiments is presented in Figures  1A-1E . Spectral acquisition was performed both in positive and negative ion resolution mode with a scan time of 1 s. Prior to SpiderMass analysis, the samples were taken out of the À20 C freezer and thawed to RT for 1 min. The spectral acquisition sequence was composed of 5 acquisitions using 10-s irradiation periods. Taking into consideration that both positive and negative ion modes were recorded, a total of 10 acquisitions per biopsy were performed. Biopsy homogeneity was verified using the morphological control prior to each acquisition to ensure that each acquisition was performed on the same histological area or to take into account the variability caused by tissue heterogeneity when needed. SpiderMass data were validated by MALDI-MSI and significantly discriminant lipids were identified, where possible, using MS/MS experiments.
MALDI Mass Spectrometry Imaging
For MALDI-MSI experiments, slides were taken out of storage, immediately dehydrated under vacuum at room temperature for 30 min, and scanned using a slide scanner (Nikon, Tokyo, Japan). 2,5-Dihydrobenzoic acid (DHB) matrix (20 mg/mL in 7:3 (v/v) MeOH/0.1% TFA in water) was manually sprayed using a syringe pump connected to an electrospray nebulizer operating at a 300 mL/h flow rate with compressed nitrogen flow pressure maintained at 1.1 bar. The nebulizer was moved uniformly throughout the entire tissue for 10 to 12 min according to tissue size. The homogeneity of the crystals was examined under a light microscope after spraying. The tissues were then analyzed using a MALDI LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with an N 2 laser (model MNL-100; LTB Lasertechnik, Berlin GmbH) which has a maximum repetition rate of 60 Hz. The maximum energy per pulse was set to 10 mJ and acquisition was performed in positive mode at 30,000 mass resolution (centered at m/z 200). Each spectrum was generated using one microscan at one microscan per step. The automatic gain control (AGC) feature was turned off and the number of laser shots was set to 10. The raster step size was set to 70 mm. The generated images were then converted to imzML format using the manufacturer software ImageQuest and exported to SCiLS. Spectral normalization was performed using the DHB peak at m/z 177. Medium edge-preserving spatial denoising, peak picking using orthogonal matching pursuit (OMP), and peak alignment by centroid matching to the mean spectrum were applied to generate the set of peaks used in subsequent analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS Classification Model Construction
For data analysis, all raw data files produced with the SpiderMass instrument were imported into the Offline Model Builder software. After importation, spectra were subjected to pre-processing steps including background subtraction, total ion count normalization, and re-binning to a 0.1 Da window. All of the processed MS spectra obtained from the 33 histologically validated samples were then used to build a principal component analysis and linear discriminant analysis (PC-LDA) classification model. The first step consisted of PCA to reduce data multidimensionality by generating features that explain most of the variance observed. These features were then subjected to supervised analysis using LDA by setting the classes that the model will be based upon. LDA attempts to classify the sample spectra and assess the model by cross validation. Cross validation was carried out by the ''leave one patient out'' method. In this method, the spectra are grouped by patient and left out one by one; at each step the model without the patient is interrogated against this model.
For tissue typing, the 2-class model (n = 2) corresponds to normal vs. cancer and the 3-class model (n = 3) to normal vs. cancer vs. necrosis. The tested spectra (n = 180) correspond to the model built using averaged MS spectra, while the others correspond to those generated using individual spectra. For tissue grading, the 4 classes correspond to normal vs. grade I vs. grade II vs. grade III. The tested spectra (n = 139) correspond to the model built using averaged MS spectra and removing the spectra from the samples for which grading was not given.
GraphPad Prism m/z intervals corresponding to loading scores with the largest contribution to the first principal components (i.e., where ideally 80% of the variance is explained) were obtained and their normalized intensities across different classes were plotted using GraphPad Prism 6. To consider the imbalance in the numbers of sample per class we used non-parametrical two-sided ANOVA (Kruskal-Wallis) followed by Dunn's test and adjusted the p value to account for the multiple comparisons with a family-wise significance and confidence level of 0.05.
Real-Time Analysis
For real-time analysis, the built model was exported to a second software module called OMB Recognition. The parameters for this analysis were: a TIC threshold of 1E +4 count for irradiation detection, a normalized intensity threshold of 1E +6 , and an outlier limit of 5 standard deviations. The software analyzes 1 scan per spectrum and has a 3 s timeout waiting for good spectrum. The cross-validated models are exported from the OMB software and then loaded in the OMB Recognition software module before any real-time piece of tissue analysis by the SpiderMass. The real-time acquired data are then directly interrogated, giving an immediate feedback using a color scale predefined from the specified classes.
Lipid Identification m/z intervals corresponding to loadings with the largest contribution to the explained variance observed in the different groups were selected for MS/MS-based identification. For these experiments, the settings were exactly the same as described in the SpiderMass section, except that a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) was used instead of the Synapt G2-S due to the high mass accuracy of the instrument. Full scans were acquired in the Orbitrap mass analyzer operated at 70,000 full width at half maximum (FWHM) resolving power (centered at m/z 400) and 1 s scan time in positive mode. The identifications were performed directly on the tissue by doing a full scan first to verify the presence of the targeted masses. Then after switching to MS/MS mode, the ions were selected ''on the fly'' for high-energy collision dissociation (HCD) with an isolation window of 0.8 m/z and with the normalized collision energy (NCE) ramp set according to the given mass. MS/MS spectra were acquired for a continuous irradiation time of 30 s. The resulting spectra were annotated manually, and assignments were verified by interrogating the high accuracy mass measurements of the precursor ions using the LIPIDMAPS database.
In Vivo and Extemporaneous Analysis at the Surgery Room For assessment in real conditions, the SpiderMass prototype was moved to the vet surgery room ( Figure 7A ). After installation, the different parts of the prototype including the MS instrument, laser system and laser probe were sterilized using gas. Additionally, the laser probe was sterilized in 70% ethanol immediately before the surgery and covered in sterile protection sleeve. The SpiderMass system was operated by a trained surgeon during a surgical operation using the same parameters both for the laser probe and the MS instrument as for the ex vivo experiments ( Figure 7B ). After analyzing canine tissues in vivo, the adjacent muscle was excised and extemporaneous analysis was conducted on the bench. Video S2 shows the use of SpiderMass in the operating theatre under sterile conditions. To demonstrate the low invasiveness of the system and its ability to produce tissue-specific molecular profiles in vivo, SpiderMass was assessed on a dog patient in vivo and for extemporaneous analysis on the bench in the course of surgery.
DATA AND SOFTWARE AVAILABILITY
The MS imaging files in imzML format and the spectral library used to construct the classification models have been deposited to the ProteomeXchange consortium: PXD010990.
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